Gastroenterology
-
Randomized Controlled Trial Multicenter Study
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial. ⋯ Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants.